Last checked at 28 Dec 2018 11:47
28 December 2018
REDX PHARMA PLC
("Redx" or "the Company")
Annual Report and Accounts
The Company announces that it will today be posting to shareholders the Annual Report and Accounts for the year ended 30 September 2018, together with the notice of the Annual General Meeting. The Annual General Meeting will be held at 11am on 23 January 2019 at the offices of WG Partners, 85 Gresham Street, London EC2V 7NQ.
The Report and Accounts are also available on the Company's website, www.redxpharma.com.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 920 |
Lisa Anson, Chief Executive Officer | |
Dominic Jackson, Chief Financial Officer | |
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker) | T: +44 20 7894 7000 |
Phil Davies | |
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson | |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/